• Medtronic Plc. rose 0.2% to $90.04 after the medical device maker reported a marginal decline in profit in the fiscal first quarter ending on July 25.

    Consolidated revenue in the quarter increased 8.4% to $8.6 billion from $7.9 billion, net income inched lower to $1.047 billion from $1.049 billion, and diluted earnings per share edged higher to 81 cents from 80 cents a year ago.

    The company guided full-year revenue to rise between 6.5% and 6.8% and non-GAAP earnings per share to rise approximately 4.5% and range between $5.60 and $5.66.
    Aug 20, 2025

  • Medtronic Plc. traded flat at $84.41 after the medical device provider reported higher revenue and earnings in the fourth quarter of 2025.

    Net sales climbed to $8.93 billion from $8.59 billion, net income edged up to $1.06 billion from $654 million, and diluted earnings per share rose to 82 cents from 49 cents a year ago.

    The medical technology company plans to separate its diabetes business into a standalone public company within 18 months.

    The company announced a cash dividend of 71 cents per share, or an annual amount of $2.84 per share, payable on July 11 to shareholders on record on June 27.

    Medtronic guided fiscal year 2026 organic revenue to grow by approximately 5%, compared to $33.54 billion, and diluted non-GAAP earnings per share to increase by 4%, compared to $5.49 a year earlier, respectively.
    May 22, 2025

  • Medtronic Plc. gained 0.3% to $86.30 after the American-Irish medical device company reported results for the fiscal 2025 third quarter.

    Revenue increased 2.5% to $8.29 billion from $8.09 billion, net income dropped to $1.29 billion from $1.32 billion, and diluted earnings per share rose to $1.01 from 99 cents a year ago.

    Sales in the cardiovascular, medical surgical, and diabetes segments marked a steady growth in the quarter, while the neuroscience segment dropped 3.7% to $769 million from $799 million in the same period last year.

    For the full year, Medtronic estimated non-GAAP earnings growth between 4.6% and 5.8% in the range of $5.44 to $5.50 per share.
    Feb 19, 2025

  • Medtronic fiscal Q2 revenue fell 3.3% to $7.6 billion and net income plunged to $427 million from $1.3 billion or 32 cents from 97 cents a year ago.
    Nov 22, 2022

    $ 80.97
  • 0.94 % 0.76
  • Last Close
  • Jan 3, 2025

Trading Volume 162,626
  • 52-Week High/Low ($)
  • 89.35 - 69.43
    Market Cap Full $ 117.2B
    Quarterly +
    2026 2025 2024 2023
    Q1 - 1.3% 5.7% 3.6%
    Q2 - - -8.8% 9.4%
    Q3 - - 9.8% -11.1%
    Q4 - - -8.9% 6%
    Monthly +
    J F M A M J J A S O N D
    2026
    - - - - - - - - - - - -
    2025
    1.3 - - - - - - - - - - -
    2024
    6.2 -4.8 4.5 -8.8 2.4 -2.5 1.2 9.8 - - - -7.5
    2023
    7.7 -1.1 -2.7 12.9 -9 6.4 -0.4 -7.1 -3.9 -10 12.3 4
    2022
    -0.6 1.5 5.7 -5.4 -4.9 -10.1 3.2 -5.1 -8.2 8.2 -9.5 -1.7
    2021
    -2.6 3.9 1 10.3 -2.8 -2 5.8 1.7 -5.5 -5 -11 -2.5
    Annually +
    2026 2025 2024 2023 2022
    MDT 0%1%-3%6%-25%

    EPS
    2023 2022 2021
    Q1 0.9 1.1 0.9
    Q2 0.9 1.1 1
    Q3 0.6 0.7 0.6
    Q4 0.7 0.3 1
    A 3.07 2.8 3.7
    52 Week High/Low
    Quarterly EPS
    Annual EPS
    Stock Price +
    Trading Volume


    Weekly Newsletter